Clinical trials / New York
Psychedelic and ketamine trials recruiting in New York
18 trials registered on ClinicalTrials.gov were recruiting at one or more sites in New York on 26 Oct 2026. By substance: Psilocybin 9, Ketamine / esketamine 5, MDMA 4. By condition: depression 8, ptsd 2, alcohol use disorder 1, opioid use disorder 1, anxiety 2, cancer and end-of-life distress 1, eating disorders 1.
From the ClinicalTrials.gov registry (US National Library of Medicine), read through its public API on 26 Oct 2026: studies marked as recruiting whose interventions name the substance. Titles, sponsors, phases, conditions and sites are the registry's own entries, written by the sponsors. We have not vetted any trial, and recruiting status changes; the registry record and the study team have the current eligibility rules.
Phase 2/3PsilocybinNCT07570654
Redefine Study: A Study Evaluating the Efficacy, Safety, and Tolerability of COMP360 in Participants With Post-traumatic Stress Disorder (Redefine)
- Conditions:
- PTSD - Post Traumatic Stress Disorder; PTSD; PTSD Symptoms; PTSD, Post Traumatic Stress Disorder
- Sponsor:
- COMPASS Pathways
- Who:
- ages 18 Years and over, 300 participants planned
- Also in:
- Canada
- NY, New York, New York
- NY, The Bronx, New York
Phase 3Ketamine / esketamineNCT07716098
A Study of Esketamine Nasal Spray Versus Placebo Spray in Adult Participants With Treatment-resistant Depression
- Conditions:
- Depressive Disorder, Treatment-Resistant
- Sponsor:
- Janssen Research & Development, LLC
- Who:
- ages 18 Years and over, 348 participants planned
- Also in:
- Japan, Taiwan
- Neurobehavioral Research Inc, Cedarhurst, New York
- The Medical Research Network, LLC, New York, New York
Phase 1PsilocybinNCT07516405
Safety and Tolerability Trial of Psilocybin in Healthy Older Adults (Psil-Pk)
- Conditions:
- Healthy Volunteer; Older Adults (65-85 Years)
- Sponsor:
- University of Colorado, Denver
- Who:
- ages 65 Years to 85 Years, 40 participants planned, accepts healthy volunteers
- New York University Langone Health, Center for Psychedelic Medicine, New York, New York
Phase 2PsilocybinNCT06796062
Psilocybin for Opioid Use Disorder (OUD)
- Conditions:
- Opioid Use Disorder
- Sponsor:
- NYU Langone Health
- Who:
- ages 18 Years to 65 Years, 480 participants planned
- StartCare, Brooklyn, New York
- NYU Langone Health, New York, New York
- VIP Community Services, Inc, The Bronx, New York
Phase 2/3PsilocybinNCT05398484
Psilocybin Therapy in Advanced Cancer
- Conditions:
- Advanced Cancer
- Sponsor:
- NYU Langone Health
- Who:
- ages 21 Years to 100 Years, 200 participants planned
- NYU Langone Health, New York, New York
Phase 4Ketamine / esketamineNCT06213324
Neural Circuit Effects of Ketamine in Depression
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 18 Years to 65 Years, 120 participants planned, accepts healthy volunteers
- Icahn School of Medicine at Mount Sinai, New York, New York
Phase 2PsilocybinNCT06349083
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
- Conditions:
- Alcohol Use Disorder
- Sponsor:
- NYU Langone Health
- Who:
- ages 18 Years to 65 Years, 200 participants planned
- NYU Langone Health, New York, New York
Phase 2MDMANCT06418178
Dose Optimization of MDMA-Assisted Therapy for PTSD (DosOp)
- Conditions:
- Posttraumatic Stress Disorder
- Sponsor:
- Bronx VA Medical Center
- Who:
- ages 18 Years and over, 60 participants planned
- James J. Peters VA Medical Center, The Bronx, New York
Phase 2Ketamine / esketamineNCT06559826
Ketamine-Assisted Psychotherapy (KAP) Compared to Ketamine Alone for the Treatment of Depression (KAP)
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 18 Years to 90 Years, 70 participants planned
- Icahn School of Medicine at Mount Sinai, New York, New York
Phase 2PsilocybinNCT06592833
Psilocybin With Pimavanserin Compared to Psilocybin Alone for the Treatment of Major Depressive Disorder
- Conditions:
- Major Depressive Disorder
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 21 Years to 80 Years, 60 participants planned
- Icahn School of Medicine at Mount Sinai, Center for Psychedelic Therapy Research, New York, New York
Phase 3Ketamine / esketamineNCT06752759
Nebulized Ketamine for the Treatment of Major Depressive Disorder
- Conditions:
- Severe Depression; Moderate Depression; Ketamine; Midazolam; Peripheral Nervous System Agents; Central Nervous System Agents; Neurotransmitter Agents; Physiologic Effects of Drugs; Sensory System Agents; Analgesics, Non-Narcotic; Anti-Inflammatory Agents, Non-Steroidal; Depressive Symptom; Hypnotics and Sedatives; Anti-anxiety Agents; Tranquilizing Agents; Psychotropic Drugs; Anesthetics Agent
- Sponsor:
- Theresa Jacob, PhD, MPH
- Who:
- ages 18 Years to 88 Years, 40 participants planned
- Maimonides Medical Center, Brooklyn, New York
Phase 2PsilocybinNCT06899165
Psilocybin-Assisted Therapy for Intergenerational Trauma
- Conditions:
- Psychological Stress; Depression; Anxiety
- Sponsor:
- Rachel Yehuda
- Who:
- ages 18 Years and over, 100 participants planned
- The Parsons Research Center for Psychedelic Healing, New York, New York
Phase 1MDMANCT07102576
MDMA-Assisted Therapy for Mental Healthcare Providers
- Conditions:
- Mental Wellbeing
- Sponsor:
- Rachel Yehuda
- Who:
- ages 18 Years and over, 30 participants planned, accepts healthy volunteers
- The Parsons Research Center for Psychedelic Healing, New York, New York
Phase 1/2PsilocybinNCT07251491
Psilocybin to Treat Depression in Spinal Cord Injury (STOP)
- Conditions:
- Spinal Cord Injury; Depression - Major Depressive Disorder; Veteran
- Sponsor:
- James J. Peters Veterans Affairs Medical Center
- Who:
- ages 22 Years and over, 30 participants planned
- James J. Peters Department of Veterans Affairs Medical Center, The Bronx, New York
Phase 2MDMANCT07303907
A Phase 2A Trial of DT402 for Autism Spectrum Disorder
- Conditions:
- Autism Spectrum Disorder; ASD
- Sponsor:
- Definium Therapeutics US, Inc.
- Who:
- ages 18 Years to 65 Years, 20 participants planned
- Spectrum Neuroscience and Treatment Institute, New York, New York
Phase 1MDMANCT07542145
MDMA Assisted Therapy for BN
- Conditions:
- Bulimia Nervosa
- Sponsor:
- Icahn School of Medicine at Mount Sinai
- Who:
- ages 18 Years and over, 40 participants planned
- Department of Psychiatry, Eating and Weight Disorders Program, New York, New York
Phase 1PsilocybinNCT07607938
Psilocybin as a Novel Therapy for Residual Anhedonia
- Conditions:
- Anhedonia; Emotional Blunting
- Sponsor:
- NYU Langone Health
- Who:
- ages 18 Years to 65 Years, 90 participants planned
- NYU Langone Health, New York, New York
Phase 4Ketamine / esketamineNCT07680140
Biomarker-Guided Antidepressant Selection (BioSelect)
- Conditions:
- Depression - Major Depressive Disorder; Treatment-resistant Depression (TRD); rTMS; Ketamine; fMRI
- Sponsor:
- Weill Medical College of Cornell University
- Who:
- ages 18 Years to 70 Years, 27 participants planned
- Weill Cornell Medicine, New York, New York